2018 Pan Pacific Lymphoma Conference
S

Beyond Checkpoint Inhibitors for Hodgkin Lymphoma

By 2018 Pan Pacific Lymphoma Conference FEATURING Stephen M. Ansell
August 2018
0 Comments
Login to view comments. Click here to Login

Featured Video

10:37
Amgen Oncology

Multiple Myeloma: Importance of Proteasome Inhibition at First Relapse

Feat. J. Abbas

Related Content

AUTOPLAY
Moffitt Cancer Center

16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Sat, Jan 18, 2020
The University of Kansas Cancer Center

KU ASH 2019 Review: Current Updates in Hematologic Diseases

Sat, Jan 18, 2020
8th ESO-SIOP Europe Masterclass in Paediatric Oncology

8th ESO-SIOP Europe Masterclass in Paediatric Oncology

Sat, Jun 6, 2020
Indy Hematology Review

17th Indy Hematology Review

Sat, Mar 21, 2020
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Fri, Feb 7, 2020
16:04
2018 Pan Pacific Lymphoma Conference

Beyond Standard Chemotherapy Novel Agents and Appraoches in HL

Feat. B. Pro
10:00
2018 Pan Pacific Lymphoma Conference

The Tumor Microenvironment Using Immune Checkpoint Inhibitors

Feat. J. Gribben
13:07
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Advanced Stage Hodgkin Lymphoma: New EvIdence in Induction, Treatment In...

Feat. P. Zinzani
11:53
Indy Hematology Review

Hodgkin Lymphoma - Revolutionized Treatment Options Using Brentuximab Ve...

Feat. B. Cheson
12:43
Loretta Nastoupil

Checkpoint Inhibitors in Hodgkin Lymphoma: When and How

24:36
Stephen M. Ansell

Hodgkin Lymphoma - Immunotherapy

12:32
Indy Hematology Review

Emerging Strategies and Treatment in Hodgkin Lymphoma

Feat. B. Cheson
05:17
Loretta Nastoupil

Combination Immunotherapy for Checkpoint Inhibitors in Lymphoma Immunoth...

24:23
Cleveland Clinic Orthopaedic & Rheumatologic Institute

Autoimmune Complications from Cancer Chemotherapy: An Emerging Field

Feat. L. Cappelli
27:01
Craig Moskowitz

Hodgkin Lymphoma - Metabolic Tumor Volume as Prognostic Factor, Role of ...

08:17
2018 Pan Pacific Lymphoma Conference

How Can We Activate the Anti-tumor Immune Response in Lymphoma?

Feat. S. Ansell
15:22
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Relapsed/Refractory Hodgkin Lymphoma - Salvage Treatments, Nivolumab and...

Feat. J. Svoboda
15:08
2018 Pan Pacific Lymphoma Conference

Immune Evasion and Engagement in Lymphoma: The Mechanisms of Impairment ...

Feat. S. Ansell
06:45
2018 Pan Pacific Lymphoma Conference

Hodgkin Lymphoma: First Relapse Options

Feat. B. Pro
10:00
2018 Pan Pacific Lymphoma Conference

Relapsed and Primary Refractory Hodgkin Lymphoma in the Near Future

Feat. C. Moskowitz
39:10
ESO Lymphoma Course

Hodgkin Lymphoma - Kairos vs. Chronos Principle & New Active Agents (Ant...

Feat. P. Johnson
17:14
Catherine Diefenbach

Beyond transplant: Relapsed and Refractory Hodgkin Lymphoma

15:48
2018 Pan Pacific Lymphoma Conference

Evalutation of patients for ASCT in Relapsed Refractory Hodgkin Lymphoma

Feat. C. Moskowitz
09:36
Catherine Diefenbach

Immunotherapy in Relapsed Refractory Hodgkin Lymphoma

15:29
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

How I Treat Early Stage Hodgkin Lymphoma: Early Stage Favorable Chemo vs...

Feat. A. Evens